Fig. 10

Immunoneutralization of BDNF in obese-prone and obese-resistant mice. Schematic representation of the protocol employed to immunoneutralize BDNF in obese-prone (OP) and obese-resistant (OR) mice (a). Body mass gain (b), body mass variation (c), and percent fat mass as determined by PET-CT scan (d) during the experimental period. e Confocal microscopy analysis of FITC-dextran endogenous fluorescence in the region of the ME; in all acquisitions, the settings of the microscope were employed (laser 488, wavelength = 405, %laser = 20%, gain = 1015, offset = − 0.3799). f Fluorescence in the ME was determined using an ImageJ software and presented as relative to control. In all experiments, n = 4; *p < 0.05. 3v third ventricle, aBDNF treated with immunoneutralizing antibody against BDNF, IgG treated with pre-immune IgG, wk week